Loading
A phase 3 trial of Rinatabart sesutecan, Bevacizumab in ovarian cancer, run by Genmab, now recruiting.
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy is a phase 3 interventional study registered as NCT07225270 by Genmab, with 544 participants planned, started 2026-04-03 and due to reach its primary completion in 2028-10. Interventions recorded: Rina-S, Bevacizumab. Conditions listed: Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC. No results are recorded here; the registry entry is the source.
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Platinum-sensitive ovarian cancer, Bevacizumab.
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).